AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00568633 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Description: Allogeneic, 5+ of 6 HLA-matched PBSC transplant from sibling, mobilized to target of 5 x 10e6 CD34+ cells/kg and \< 7 x 10e8 CD3+ cells/kg.
Study NCT00568633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG)
Description: 1.5 mg/kg for 5 days by IV
Study NCT00568633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSP)
Description: 6.25 mg/kg twice daily oral
Study NCT00568633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: 15 mg/kg twice daily oral
Study NCT00568633 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (TLI)
Description: 80 cGy/fraction radiotherapy in 10 fractions.
Study NCT00568633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate
Description: 1.0 mg/kg for 5 days by IV
Study NCT00568633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best standard care
Description: Intervention consist of:~* Consolidation chemotherapy (3-4 cycles of cytarabine +/- an anthracycline agent, or other consolidation)~* Autologous transplantation~* Non-Myeloablative unrelated-donor transplant, +/- TLI and ATG conditioning~* Umbilical cord blood transplantation~* Haploidentical transplantation
Study NCT00513825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate
Description: IV solution of NaCl 0.45% (Arm 1) or IV 75 cc of sodium bicarbonate 8.4% solved in 1 liter of NaCl 0.45% (Arm 2) . Each fluid is infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.
Study NCT02983279 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Undergo caloric restriction diet
Study NCT02983279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Undergo counselor-led dietary counseling
Study NCT04364490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Copernicus noVF
Description: Advanced gait training sessions by the computerized BWS system, named Copernicus®, without visual feedback.
Study NCT04364490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Copernicis VF-Plus
Description: Advanced gait training session with the addition of visual feedback ensuring a real-time interactive control of locomotor performance.
Study NCT02983279 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic
Description: Undergo standard of care surgery
Study NCT02524483 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Challenge Program
Description: The Therapeutic Challenge Program will consist of a 5 minute warm-up, 20 minutes of challenging balance training, and 20 minutes of challenging treadmill and overground walking.
Study NCT02524483 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise Program
Description: The Therapeutic Exercise Program will consist of 15 minutes of strength training and flexibility exercises, 15 minutes of balance exercises, and 15 minutes of treadmill walking.
Study NCT04242641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WW
Description: WW is a structured lifestyle modification, weight-loss programme involving a programme for healthy eating, physical activity and positive mindset and support via attendance at local WW workshops and digital tools.
Study NCT01251536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose escalation of cetuximab
Description: Dose, frequency \& treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)~Arm allocation at day 22:~Patients with skin toxicity grade 0 will follow an increasing dose schedule: on days 22 and 29 they will receive 350 mg/m2 and from day 36 onwards, 500 mg/m2 weekly
Study NCT01251536 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard first line treatment with cetuximab + Folfiri
Description: Dose, frequency \& treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)~Arm allocation at day 22:~Patients with skin toxicity grade 1-4 or other significant toxicity who are not eligible for dose escalation will continue on the standard dose of cetuximab: 250 mg/m2 weekly.
Study NCT01146457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Active dosage
Study NCT04364490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Usual care
Study NCT04829162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother without obesity, daughter with obesity
Description: Participants in this group were shown an image of a mother without obesity and a daughter with obesity.
Study NCT04829162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother without obesity, daughter without obesity
Description: Participants in this group were shown an image of a mother without obesity and a daughter without obesity.
Study NCT04829162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother with obesity, son with obesity
Description: Participants in this group were shown an image of a mother with obesity and a son with obesity.
Study NCT04829162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother with obesity, son without obesity
Description: Participants in this group were shown an image of a mother with obesity and a son without obesity.
Study NCT04829162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother without obesity, son with obesity
Description: Participants in this group were shown an image of a mother without obesity and a son with obesity.
Study NCT01146457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline Control
Study NCT00272662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Study NCT01331252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: semi-recumbent
Description: Patient rests in a semi-recumbent body position
Study NCT01331252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supine
Description: Patient rests in a supine position
Study NCT02720172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Home Exercise Program
Description: The early home exercise program is a 6-week program of home exercises with weekly phone calls to monitor progression and compliance.
Study NCT02720172 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual care involves standard postoperative management under the direction of the treating surgeon.
Study NCT03124667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Games
Description: The game training will emphasize general and exercise-specific dual task processing, self-priming and certainty training.
Study NCT03124667 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Videos
Description: The video training will emphasize health and educational information.
Study NCT03079713 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Handheld vibrator triggered during intravitreal injection for wet ARMD
Description: A vibratory device cleaned with alcohol swabs between each use will be attached to the injectors' finger, placed on the lower eyelid of the treatment eye, and triggered during intravitreal injection
Study NCT03079713 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normal eye esthesiometry with and without vibration
Description: Healthy patients will undergo corneal and conjunctival esthesiometry with and without triggering of the wearable vibrator placed upon the lower lid of a single eye.
Study NCT03079713 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Handheld vibrator not triggered during intravitreal injection for wet ARMD
Description: Control group undergoing standard intravitreal injection without triggering of the vibrator.
Study NCT02328378 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Quadratus Lumborum block
Description: Patients will receive a bilateral Quadratus Lumborum block using 0.125% Bupivacaine in a dose of 0.2ml/kg body weight, after the end of surgery.
Study NCT02328378 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum block
Description: Patients will receive a bilateral Quadratus Lumborum block using 0.125% Bupivacaine in a dose of 0.2ml/kg body weight, after the end of surgery.
Study NCT00943449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4SC-201
Description: oral administration
Study NCT00943449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: oral administration
Study NCT04829162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother without obesity, son without obesity
Description: Participants in this group were shown an image of a mother without obesity and a son without obesity.
Study NCT04829162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Father with obesity, daughter with obesity
Description: Participants in this group were shown an image of a father with obesity and a daughter with obesity.
Study NCT04829162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Father with obesity, daughter without obesity
Description: Participants in this group were shown an image of a father with obesity and a daughter without obesity.
Study NCT04829162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Father without obesity, daughter with obesity
Description: Participants in this group were shown an image of a father without obesity and a daughter with obesity.
Study NCT04829162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Father without obesity, daughter without obesity
Description: Participants in this group were shown an image of a father without obesity and a daughter without obesity.
Study NCT04829162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Father with obesity, son with obesity
Description: Participants in this group were shown an image of a father with obesity and a son with obesity.
Study NCT04829162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Father with obesity, son without obesity
Description: Participants in this group were shown an image of a father with obesity and a son without obesity.
Study NCT04829162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Father without obesity, son with obesity
Description: Participants in this group were shown an image of a father without obesity and a son with obesity.
Study NCT04829162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Father without obesity, son without obesity
Description: Participants in this group were shown an image of a father without obesity and a son without obesity.
Study NCT02269540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: selective serotonin reuptake inhibitor
Study NCT04334798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active exercises of the pelvic floor muscles & Electrostimulation & Biofeedback
Description: See information included in arm/group descriptions.
Study NCT04334798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active exercises of the pelvic floor muscles & Biofeedback
Description: See information included in arm/group descriptions.
Study NCT04334798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active exercises of the pelvic floor muscles & Transabdominal US Biofeedback
Description: See information included in arm/group descriptions.
Study NCT04334798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active exercises of the pelvic floor muscles & Electrostimulation &Transabdominal US Biofeedback
Description: See information included in arm/group descriptions.
Study NCT00004562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta adrenergic blockers
Description: Participants will receive beta adrenergic blockers.
Study NCT00004562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta adrenergic blockers
Description: Participants will receive beta adrenergic blockers.
Study NCT00004562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet inhibitors
Description: Participants will receive platelet inhibitors.
Study NCT00004562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet inhibitors
Description: Participants will receive platelet inhibitors.
Study NCT00004562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PTCA and stents
Description: Participants will undergo percutaneous coronary intervention (PTCA) and coronary stenting.
Study NCT00004562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE Inhibitors
Description: Participants will receive ACE inhibitors.
Study NCT00004562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE Inhibitors
Description: Participants will receive ACE inhibitors.
Study NCT03004820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning
Description: RIC consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on bilateral upper limbs twice a day. Medication strategy is based on physician's best judgement.
Study NCT03010098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual-Loop TCI
Description: the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46
Study NCT03010098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open-Loop TCI
Description: the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
Study NCT04611789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3832479
Description: Administered subcutaneously
Study NCT04611789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously
Study NCT02235662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFV IVR
Study NCT02235662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFV/LNG IVR
Study NCT02235662 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IVR
Study NCT04274114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L Glutamine
Description: Powder
Study NCT04274114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Powder
Study NCT00999050 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric bypass for diabetic patients <35 BMI
Description: The operation is performed under general anesthesia. It is done laparoscopically, meaning that several small openings are made in the abdomen for insertion of long, thin surgical instruments, one with an attached camera. The operation is video monitored. The top of the stomach is divided across, leaving a small pouch for food. The rest of the stomach remains but can receive no food. The gut is divided just past the stomach, and it is attached to the small stomach pouch so that food can get back into the bowel. A second connection is made so that the bile and digestive juices pass into the bowel with the food.
Study NCT00914394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NG-monomethyl-L-arginine (L-NMMA)
Description: bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes
Study NCT00914394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NG-monomethyl-L-arginine (L-NMMA)
Description: bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes
Study NCT00914394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: 1µg/kg/min, infusion period 20 minutes
Study NCT00914394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phenylephrine
Description: 1µg/kg/min, infusion period 20 minutes
Study NCT00914394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physiological saline solution (as placebo)
Description: infusion period 20 minutes
Study NCT00914394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline solution (as placebo)
Description: infusion period 20 minutes
Study NCT00914394 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Doppler Flowmetry
Description: Measurements will be performed at the neuroretinal rim to assess ONH blood flow.
Study NCT00914394 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Laser Doppler Flowmetry
Description: Measurements will be performed at the neuroretinal rim to assess ONH blood flow.
Study NCT00914394 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goldmann applanation tonometer
Description: intraocular pressure measurements
Study NCT00914394 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Goldmann applanation tonometer
Description: intraocular pressure measurements
Study NCT00914394 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suction cup
Description: Experimental stepwise increase of intraocular pressure while measurement of optic nerve head blood flow.
Study NCT00914394 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Suction cup
Description: Experimental stepwise increase of intraocular pressure while measurement of optic nerve head blood flow.
Study NCT02269540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: selective serotonin reuptake inhibitor
Study NCT02269540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Description: natural health product
Study NCT02269540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Existing depression medication treatment
Description: Continuation of depression medication treatment already taken prior to study enrollment except for drugs with affinity for MAO-A or potentially influencing MAO-A levels, including phenelzine, tranylcypromine, moclobemide, cytomel and lithium
Study NCT00512629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: Omegaven is a fish based intravenous fat emulsion
Study NCT00512629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid
Description: Intralipid is a plant based intravenous fat emulsion
Study NCT04085640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Obturator nerve block with ropivacaine 0.2%.
Description: 20 milliliters of ropivacaine 2 mg/mL will be injected in the interfacial plane between the pectineus and external obturator muscles.
Study NCT04085640 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Obturator nerve block with isotonic saline
Description: 20 milliliters of isotonic saline will be injected in the interfacial plane between the pectineus and external obturator muscles.
Study NCT02380989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ayurveda
Description: Ayurveda combinations in the form of gel and patches were applied on acute pain site.
Study NCT03929094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel for Injection（Albumin Bound）
Description: Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
Study NCT03929094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
Study NCT01458093 — intervention group
Intervention type: OTHER
Intervention: colonoscopy
Description: evaluation of surveillance timing adequacy as compared to the guidelines
Study NCT03647189 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Hybrid Fractional Laser
Description: Hybrid Fractional Laser
Study NCT03647189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Fractional Laser
Description: Hybrid Fractional Laser
Study NCT00930137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isocaloric for week diet
Description: Consumption of the 2 experimental diets~1. a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal);~2. a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal).
Study NCT00930137 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isocaloric for week diet
Description: Consumption of the 2 experimental diets~1. a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal);~2. a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal).